Efficacy and safety outcomes of single-agent ibrutinib therapy in chronic lymphocytic leukemia and relapsed/refractory mantle-cell lymphoma

İbrahim Ethem Pınar; Vildan Ozkocaman

Makale detayları

Efficacy and safety outcomes of single-agent ibrutinib therapy in chronic lymphocytic leukemia and relapsed/refractory mantle-cell lymphoma

Yazarlar:

İbrahim Ethem Pınar | Vildan Ozkocaman

Yayıncı:

Prusa Medical Publishing

Ana Başlıklar:

Haematological Tumours

Dergi:

The European Research Journal Vol.9 Issue 6, pp.1483-1492

Belge Tipi:

Makale

Yayın Tarihi:

4/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001294111

pISSN:

2149-3189

Anahtar kelimeler:

Özet:

 Objectives: We aimed to evaluate patients using ibrutinib for the treatment of chronic lymphocytic leukemia CLL and relapsedrefractory mantle-cell lymphoma MCL, focusing on high-risk subgroups, predictors of efficacy, response levels, and safety profile. Methods: This retrospective cohort study included adult patients diagnosed with CLL and relapsedrefractory MCL who were started on ibrutinib as a single-agent between May 2015 and December 2021 in Bursa Uludag University, Department of Hematology. Results: Of the 45 patients 23 CLL, 22 MCL started on ibrutinib, the median age was 65 range: 48-86 years, and 66.7 were male. Del17p was present in 47.8 of CLL patients; there was no remarkable difference between del17p status and the rates of achieving CR. The median follow-up with ibrutinib treatment in CLL patients was 13.3 range: 0.3-77.8 months. In univariate analysis, progression-free survival PFS and overall survival OS were associated with the advanced Eastern Cooperative Oncology Group ECOG score  p  0.003 and p  0.004, respectively, and  2 lines treatment regimens before ibrutinib  p  0.016 and p  0.050, respectively. In multivariate analysis, the ECOG performance status remained significant for OS. The median use of ibrutinib for MCL patients was 6 range: 1-48 months, and the proportion of patients who achieved CR was 27.3. In the univariate analysis of MCL patients, the ECOG performance status for PFS and OS was statistically significant  p  0.045 and p  0.016, respectively. Patients most common non-hematological adverse events were pneumonia and urinary tract infection. Conclusions: Our investigation of patient outcomes treated outside clinical trials confirms ibrutinibs sufficient efficacy and safety profile in CLL and relapsedrefractory MCL.

 Objectives: We aimed to evaluate patients using ibrutinib for the treatment of chronic lymphocytic leukemia CLL and relapsedrefractory mantle-cell lymphoma MCL, focusing on high-risk subgroups, predictors of efficacy, response levels, and safety profile. Methods: This retrospective cohort study included adult patients diagnosed with CLL and relapsedrefractory MCL who were started on ibrutinib as a single-agent between May 2015 and December 2021 in Bursa Uludag University, Department of Hematology. Results: Of the 45 patients 23 CLL, 22 MCL started on ibrutinib, the median age was 65 range: 48-86 years, and 66.7 were male. Del17p was present in 47.8 of CLL patients; there was no remarkable difference between del17p status and the rates of achieving CR. The median follow-up with ibrutinib treatment in CLL patients was 13.3 range: 0.3-77.8 months. In univariate analysis, progression-free survival PFS and overall survival OS were associated with the advanced Eastern Cooperative Oncology Group ECOG score  p  0.003 and p  0.004, respectively, and  2 lines treatment regimens before ibrutinib  p  0.016 and p  0.050, respectively. In multivariate analysis, the ECOG performance status remained significant for OS. The median use of ibrutinib for MCL patients was 6 range: 1-48 months, and the proportion of patients who achieved CR was 27.3. In the univariate analysis of MCL patients, the ECOG performance status for PFS and OS was statistically significant  p  0.045 and p  0.016, respectively. Patients most common non-hematological adverse events were pneumonia and urinary tract infection. Conclusions: Our investigation of patient outcomes treated outside clinical trials confirms ibrutinibs sufficient efficacy and safety profile in CLL and relapsedrefractory MCL.

 Objectives: We aimed to evaluate patients using ibrutinib for the treatment of chronic lymphocytic leukemia CLL and relapsedrefractory mantle-cell lymphoma MCL, focusing on high-risk subgroups, predictors of efficacy, response levels, and safety profile. Methods: This retrospective cohort study included adult patients diagnosed with CLL and relapsedrefractory MCL who were started on ibrutinib as a single-agent between May 2015 and December 2021 in Bursa Uludag University, Department of Hematology. Results: Of the 45 patients 23 CLL, 22 MCL started on ibrutinib, the median age was 65 range: 48-86 years, and 66.7 were male. Del17p was present in 47.8 of CLL patients; there was no remarkable difference between del17p status and the rates of achieving CR. The median follow-up with ibrutinib treatment in CLL patients was 13.3 range: 0.3-77.8 months. In univariate analysis, progression-free survival PFS and overall survival OS were associated with the advanced Eastern Cooperative Oncology Group ECOG score  p  0.003 and p  0.004, respectively, and  2 lines treatment regimens before ibrutinib  p  0.016 and p  0.050, respectively. In multivariate analysis, the ECOG performance status remained significant for OS. The median use of ibrutinib for MCL patients was 6 range: 1-48 months, and the proportion of patients who achieved CR was 27.3. In the univariate analysis of MCL patients, the ECOG performance status for PFS and OS was statistically significant  p  0.045 and p  0.016, respectively. Patients most common non-hematological adverse events were pneumonia and urinary tract infection. Conclusions: Our investigation of patient outcomes treated outside clinical trials confirms ibrutinibs sufficient efficacy and safety profile in CLL and relapsedrefractory MCL.

 Objectives: We aimed to evaluate patients using ibrutinib for the treatment of chronic lymphocytic leukemia CLL and relapsedrefractory mantle-cell lymphoma MCL, focusing on high-risk subgroups, predictors of efficacy, response levels, and safety profile. Methods: This retrospective cohort study included adult patients diagnosed with CLL and relapsedrefractory MCL who were started on ibrutinib as a single-agent between May 2015 and December 2021 in Bursa Uludag University, Department of Hematology. Results: Of the 45 patients 23 CLL, 22 MCL started on ibrutinib, the median age was 65 range: 48-86 years, and 66.7 were male. Del17p was present in 47.8 of CLL patients; there was no remarkable difference between del17p status and the rates of achieving CR. The median follow-up with ibrutinib treatment in CLL patients was 13.3 range: 0.3-77.8 months. In univariate analysis, progression-free survival PFS and overall survival OS were associated with the advanced Eastern Cooperative Oncology Group ECOG score  p  0.003 and p  0.004, respectively, and  2 lines treatment regimens before ibrutinib  p  0.016 and p  0.050, respectively. In multivariate analysis, the ECOG performance status remained significant for OS. The median use of ibrutinib for MCL patients was 6 range: 1-48 months, and the proportion of patients who achieved CR was 27.3. In the univariate analysis of MCL patients, the ECOG performance status for PFS and OS was statistically significant  p  0.045 and p  0.016, respectively. Patients most common non-hematological adverse events were pneumonia and urinary tract infection. Conclusions: Our investigation of patient outcomes treated outside clinical trials confirms ibrutinibs sufficient efficacy and safety profile in CLL and relapsedrefractory MCL.

Makale detayları

Efficacy and safety outcomes of single-agent ibrutinib therapy in chronic lymphocytic leukemia and relapsed/refractory mantle-cell lymphoma

Yazarlar:

İbrahim Ethem Pınar | Vildan Ozkocaman

Yayıncı:

Prusa Medical Publishing

Ana Başlıklar:

Haematological Tumours

Dergi:

The European Research Journal Vol.9 Issue 6, pp.1483-1492

Belge Tipi:

Makale

Yayın Tarihi:

4/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001294111

pISSN:

2149-3189

Ibrutinib

efficiency

safety

chronic lymphocytic leukemia

mantle-cell lymphoma

Sayı

Makale detayları

Efficacy and safety outcomes of single-agent ibrutinib therapy in chronic lymphocytic leukemia and relapsed/refractory mantle-cell lymphoma

Yazarlar: İbrahim Ethem Pınar | Vildan Ozkocaman

Yayıncı: Prusa Medical Publishing

Ana Başlıklar: Haematological Tumours

Dergi: The European Research Journal Vol.9 Issue 6, pp.1483-1492

Belge Tipi: Makale

Yayın Tarihi: 4/2023

Belge Dili: İngilizce

Document ID (Org No.): 2001294111

pISSN: 2149-3189

Ibrutinib

efficiency

safety

chronic lymphocytic leukemia

mantle-cell lymphoma

Sayı

Yazarlar:

İbrahim Ethem Pınar | Vildan Ozkocaman

Yayıncı:

Prusa Medical Publishing

Ana Başlıklar:

Haematological Tumours

Dergi:

The European Research Journal Vol.9 Issue 6, pp.1483-1492

Belge Tipi:

Makale

Yayın Tarihi:

4/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001294111

pISSN:

2149-3189